Search clinical trials for: Recurrent Metastatic Squamous Cell Carcinoma Head and Neck

Total 475349 results

Yonsei University

Unknown

Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy

HNSCC

Korea, Republic of
Pierre Fabre Medicament

Completed

Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer

Recurrent or Metastatic Head and Neck Carcinoma

France
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer

Head and Neck Cancer

United States
Yonsei University

Unknown

A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC)

Inoperable or Recurrent or Metastatic Esophageal Squamous Carcinoma

Korea, Republic of
Yonsei University

Unknown

A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus

Squamous Cell Carcinoma of Esophagus

Korea, Republic of
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer

Head and Neck Cancer

United States
National Cancer Institute (NCI)

Completed

Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma

United States
Amgen
Takeda

Completed

A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of Head and Neck
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Head and Neck Cancer

United States
Amgen

Completed

PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck

United States, Belgium, Czechia, Spain, Austria, France, Lithuania, Puerto Rico, Slovakia
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Head and Neck Cancer

Canada
Shanghai Ninth People's Hospital Affiliated to...

Unknown

A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers

Head and Neck Squamous Cell Carcinoma

China
National Cancer Institute (NCI)

Completed

Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal... and other conditions

United States
Daiichi Sankyo, Inc.

Completed

Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United Kingdom
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy

Head and Neck Squamous Cell Carcinoma

Germany, United Kingdom, United States, Spain, Italy, Canada, Poland, Russian Federation, Switzerland, Thailand, Korea, Republic of, Hungary, Ireland, Australia, Taiwan, France, India, Japan
Yonsei University

Unknown

An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Korea, Republic of
Medical University of South Carolina

Completed

Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer

Head and Neck Cancer

United States
Ezra Cohen
SignalRX Pharmaceuticals, Inc.

Terminated

SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma

United States
Ohio State University Comprehensive Cancer Center
National Comprehensive Cancer Network

Completed

Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
Cascadian Therapeutics Inc.

Completed

Phase 1 and 2 Study of PX-866 and Cetuximab

Incurable Metastatic Colorectal Carcinoma | Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

United States, Canada
Eli Lilly and Company

Completed

Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

Head and Neck Cancer

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
Boehringer Ingelheim

Completed

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Head and Neck Neoplasms | Carcinoma, Squamous Cell

United States, Argentina, Austria, Belgium, Brazil, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, Mexico, Russian Federation, South Africa, Spain, Sweden, Switzerland
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Esophagus | Recurrent Esophageal Cancer | Stage IV Esophageal Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma... and other conditions

United States
National Cancer Institute (NCI)

Completed

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company; National Comprehensive Cancer Network

Completed

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Squamous Cell Cancer | Head and Neck

United States
Julie E. Bauman, MD, MPH
Bristol-Myers Squibb

Terminated

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

Squamous Cell Carcinoma Of The Head And Neck

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); National Comprehensive Cancer Network

Completed

Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer

Gastric Adenocarcinoma | Recurrent Gastric Carcinoma | Esophageal Undifferentiated Carcinoma | Gastric Squamous Cell Carcinoma | Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer | Stage IV Esophageal Adenocarcinoma | Stage... and other conditions

United States
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Recurrent Squamous Cell Carcinoma of the Nasopharynx | Stage IV Squamous Cell Carcinoma of the Nasopharynx

United States, Singapore, China
Seoul National University Hospital

Unknown

A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy

Head and Neck Neoplasms | HNSCC

Korea, Republic of
AstraZeneca

Completed

SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) (SUPREME-HN)

Squamous Cell Carcinoma of the Head and Neck

United States, Italy, Korea, Republic of, Spain, Greece, Germany, Japan
National Cancer Institute (NCI)

Completed

A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Carcinoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer

Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary | Recurrent Oral Cavity... and other conditions

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

Pain | Head and Neck Cancer | Mucositis | Oral Complications of Radiation Therapy

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871

Breast Cancer | Head and Neck Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Bladder Cancer
Genentech, Inc.

Completed

A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

Head and Neck Cancer

Belgium, United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Head and Neck Cancer

United States
Cliniques universitaires Saint-Luc- Université...

Completed

Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (RACATREX)

Squamous Cell Carcinoma of the Head and Neck

Belgium, Luxembourg
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Biomarkers in Patients With Head and Neck Cancer

Head and Neck Cancer
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Blood Sample Analysis in Predicting Overall Survival in Patients With Recurrent or Metastatic Head and Neck Cancer

Head and Neck Cancer
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Biomakers in Tissue Samples From Patients With Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Previously Treated With Cisplatin With or Without Cetuximab

Head and Neck Cancer
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Biomarkers in Tissue Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on ECOG-E1395 and ECOG-E3301

Head and Neck Cancer
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Studying Biomarkers in Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on E1302 Trial

Head and Neck Cancer
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397

Head and Neck Cancer
Groupe Oncologie Radiotherapie Tete et Cou
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (TPEx)

Squamous Cell Head and Neck Carcinoma | Recurrent or Metastatic Disease

France, Belgium
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Carcinoma, Squamous Cell

India
National Cancer Institute (NCI)

Terminated

Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Metastatic Squamous Cell Carcinoma in... and other conditions

Canada
Samyang Biopharmaceuticals Corporation

Unknown

Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC

Head and Neck Squamous Cell Carcinoma

Korea, Republic of
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

Breast Cancer | Head and Neck Cancer | Lung Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific

Search clinical trials for: Recurrent Metastatic Squamous Cell Carcinoma Head and Neck

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations